Oculis Holding AG (OCS) Cash & Current Investments (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Cash & Current Investments of $304.9 million in Q1 2026, up 14.42% quarter-over-quarter from $266.5 million in Q4 2025, and up 83.07% on a YoY basis from $166.6 million in Q1 2025.
Oculis Holding AG (OCS) Cash & Current Investments (2021 - 2026) Analysis & Trends
Oculis Holding AG's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $304.9 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 83.07% year-over-year to $304.9 million; the TTM figure through Mar 2026 stood at $304.9 million (up 83.07% YoY), while the FY2025 annual figure was $266.5 million, up 136.64% from the prior year.
- Cash & Current Investments was $304.9 million for Q1 2026 at Oculis Holding AG, up from $266.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $304.9 million in Q1 2026 to a low of $20.5 million in Q4 2022.
- Historically, Cash & Current Investments has averaged $124.4 million across 5 years, with a median of $110.5 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments slumped 59.08% in 2022, then soared 402.89% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $20.5 million in 2022, then surged by 301.3% to $82.4 million in 2023, then soared by 36.65% to $112.6 million in 2024, then surged by 136.64% to $266.5 million in 2025, then grew by 14.42% to $304.9 million in 2026.
- The last three Cash & Current Investments figures came in at $304.9 million (Q1 2026), $266.5 million (Q4 2025), and $158.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 304.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304.95 Mn |
| Dec 31, 2025 | 266.52 Mn |
| Sep 30, 2025 | 158.07 Mn |
| Jun 30, 2025 | 193.62 Mn |
| Mar 31, 2025 | 166.57 Mn |
| Dec 31, 2024 | 112.63 Mn |
| Sep 30, 2024 | 124.85 Mn |
| Jun 30, 2024 | 124.29 Mn |
| Mar 31, 2024 | 107.58 Mn |
| Dec 31, 2023 | 82.42 Mn |
| Sep 30, 2023 | 108.30 Mn |
| Jun 30, 2023 | 102.17 Mn |
| Mar 31, 2023 | 21.39 Mn |
| Dec 31, 2022 | 20.54 Mn |
| Sep 30, 2022 | 47.92 Mn |
| Jun 30, 2022 | 48.05 Mn |
| Dec 31, 2021 | 50.19 Mn |